NCT03437005 Alternation in the Human Microbiome With Commonly Used Topical Medications
| NCT ID | NCT03437005 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of California, Davis |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2013-01-28 |
| Primary Completion | 2026-09-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2013-01-28 with a primary completion date of 2026-09-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The global aim of this study is to investigate how the human microbiome changes from baseline with commonly used topical medications such as topical antifungals, low to mid potency topical steroids and emollients. The specific aims are as follows: 1. Investigate whether ketoconazole cream, a commonly used topical antifungal, causes alterations in the human skin microbiome with short-term use. 2. Investigate whether desonide 0.05 % ointment, a commonly used low potency topical steroid, alters the human microbiome with short-term use.
Eligibility Criteria
The inclusion criteria: • Adults at least 18 years of age. The exclusion criteria: * Individuals with known chronically active skin diseases, including atopic dermatitis, psoriasis, seborrheic dermatitis, other autoimmune and inflammatory skin conditions. * Patients with a history of skin cancer, multiple nevi, or other isolated lesions will not be excluded. * Individuals who have used topical, intravenous, intramuscular, or oral antibiotics within the last 6 months * Individuals with known allergies to any of the study medications. * Individuals younger than 18 years of age. * Adults unable to consent * Non-English speaking individuals. Given the complexity in the instructions that subjects will need to follow for proper sample collection, we will not seek to recruit non-English speaking individuals for this pilot study. * Prisoners
Contact & Investigator
Emanual Maverakis, MD
PRINCIPAL INVESTIGATOR
UC Davis
Frequently Asked Questions
Who can join the NCT03437005 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03437005 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03437005 currently recruiting?
Yes, NCT03437005 is actively recruiting participants. Contact the research team at emaverakis@ucdavis.edu for enrollment information.
Where is the NCT03437005 trial being conducted?
This trial is being conducted at Sacramento, United States.
Who is sponsoring the NCT03437005 clinical trial?
NCT03437005 is sponsored by University of California, Davis. The principal investigator is Emanual Maverakis, MD at UC Davis. The trial plans to enroll 24 participants.